Acadia Pharma (ACAD) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 8, 2021 4:05 PM EST- 3Q21 net sales of $131.6 million, a 9% increase over 3Q20
- FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.
Our third-quarter results reflect volume growth across all channels and our strong relative performance underscores our commercial teams ability to drive sales of NUPLAZID in a challenging environment, said Steve Davis, Chief Executive Officer. As we... More
